AUG 12·SEC EDGARLow
Watton Corey Michael sold $138K of ZVRA
Watton Corey Michael sold 12,300 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.25 ($0.14M total) on 2026-08-10.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ZVRA
ZEVRA THERAPEUTICS, INC.
Price · $ZVRAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ZVRA in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $138K 1 txs
Watton Corey Michael1× · $138K
10b5-1 share of filings0%
Top stories · $ZVRAMore →
AUG 7·yahoo.com
Zevra Therapeutics Q2 Earnings Call Highlights
Zevra Therapeutics (NASDAQ:ZVRA) reported Q2 updates on MIPLYFFA, including high refill, compliance and persistence, and payer coverage of 69% of covered lives. Net reimbursements were $9 million. In the EU, Zevra will re-examine arimoclomol after a CHMP negative opinion, with an expected Q4 decision. Cash was $260.2 million.
AUG 5·SEC EDGAR 8-K
ZEVRA THERAPEUTICS, INC. (ZVRA): Results of Operations and Financial Condition
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zvra-20260805xex991earnings.htm EX-99.1 Document Exhibit 99.1 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025
ZVRA sentiment & insider activity
Recent ZVRA coverage spans regulation, earnings and financial news.
In the last 30 days, ZVRA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($138K). The most active reporter was Watton Corey Michael with 1 filing.
What's driving ZVRA
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
EU regulatory re-examination is a near-term binary catalyst for arimoclomol, with Q4 CHMP opinion timing.
Near-term focus is on commercial execution and regulatory path in Europe, with cash runway supporting ongoing arimoclomol and celiprolol Phase 3 work.
Regulatory setback in Europe increases approval risk and can pressure valuation until re-examination outcome is clearer.
A CHMP negative opinion is a regulatory setback that can delay or block European commercialization, increasing downside risk to timelines and valuation.
alphai scores every news story that mentions ZVRA with an AI model for sentiment and relevance, and aggregates insider trades from ZEVRA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ZVRA
Score
Watton Corey Michael sold $138K of ZVRA
Watton Corey Michael sold 12,300 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.25 ($0.14M total) on 2026-08-10.
2 min readZevra Therapeutics Q2 Earnings Call Highlights
Zevra Therapeutics (NASDAQ:ZVRA) reported Q2 updates on MIPLYFFA, including high refill, compliance and persistence, and payer coverage of 69% of covered lives. Net reimbursements were $9 million. In the EU, Zevra will re-examine arimoclomol after a CHMP negative opinion, with an expected Q4 decision. Cash was $260.2 million.
4 min readZEVRA THERAPEUTICS, INC. (ZVRA): Results of Operations and Financial Condition
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zvra-20260805xex991earnings.htm EX-99.1 Document Exhibit 99.1 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025
6 min readZevra To Appeal EMA's Negative Opinion On Arimoclomol For Niemann-Pick Disease Type C
Zevra Therapeutics said the EMA CHMP issued a negative opinion on its marketing authorization application for arimoclomol to treat Niemann-Pick disease type C. Zevra plans to request a re-examination and submit supporting explanations, while continuing expanded access to generate real-world evidence. ZVRA shares closed at $9.53, down 23.92% on the day.
3 min read
Zevra Slips on Revealing Opinion on Treatment
Zevra Therapeutics (NASDAQ: ZVRA) fell after the EMA CHMP issued a negative opinion on its marketing authorization application for arimoclomol to treat Niemann-Pick disease type C. Zevra said it will request a re-examination and provide supporting explanations, and it continues expanded access to support eligible patients and gather real-world evidence.
2 min readTop Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads
Biotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.
7 min readZevra Therapeutics extends MIPLYFFA exclusivity to 2041
Zevra Therapeutics said it filed a patent for MIPLYFFA (arimoclomol) to be listed in the FDA’s Orange Book, with protection extending to 2041. The company said the Orange Book listing would strengthen MIPLYFFA’s exclusivity and could trigger an automatic stay on generic approvals if challenged. Zevra shares rose more than 9.5% on Monday.
3 min readZEVRA THERAPEUTICS, INC. (ZVRA): Submission of Matters to a Vote of Security Holders
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zvra-20260604 false 0001434647 0001434647 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________________________________ FORM 8-K ____________________________________________
2 min read
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics (Nasdaq: ZVRA) said it granted inducement stock options to four new employees totaling 33,000 shares under its 2023 Employment Inducement Award Plan, approved by the Compensation Committee. Options vest over four years: 25% after the first anniversary of each employee’s start date, with the remainder in three equal annual installments, subject to continued employment.
2 min read
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Zevra Therapeutics has sold its serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, to Commave Therapeutics SA for $50 million. This agreement resolves a lawsuit initiated by Commave in 2024 concerning a 2019 license agreement. Zevra stated that this transaction allows them to focus on their mission of providing therapies for rare diseases and they are now debt-free.
3 min read